Render Target: STATIC
Render Timestamp: 2024-11-22T11:08:34.650Z
Commit: 5c4accf06eb7154018ba3f54329c7590f97f534a
XML generation date: 2024-09-30 01:53:14.439
Product last modified at: 2024-11-11T20:00:08.887Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

EREG (D4O5I) Rabbit mAb #12048

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 17,19, 30
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    EREG (D4O5I) Rabbit mAb recognizes endogenous levels of proepiregulin and the C-terminal propeptide of the EREG protein.  It does not recognize the mature form of EREG.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Glu155 of human EREG protein.

    Background

    Epiregulin (EREG) belongs to the epidermal growth factor (EGF) family and is a ligand for the EGF receptor (EGFR) and ErbB4 (1-3). The binding of EREG to homodimers, as well as heterodimers containing EGFR or ErbB4, leads to receptor activation and downstream signaling to promote cell growth and proliferation (4-6). In normal human tissue, moderate levels of EREG are expressed in the placenta and peripheral blood macrophages. Research studies have shown that EREG is expressed at high levels in numerous cancer cell lines, and EREG expression is correlated with primary cancer aggresiveness/metastases (7-11). In addition to its involvement in tumorigenesis, a variant of EREG has also been shown to be associated with tuberculosis susceptibility (12). EREG is synthesized as a ~30 kDa glycosylated membrane bound proepiregulin form (19 kDa when not glycosylated) and through subsequent proteolytic cleavage is processed to a 17 kDa C-terminal propeptide, and the 6kDa mature form of epiregulin (13).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.